NCT05361395 2026-03-03First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)AmgenPhase 1 Active not recruiting184 enrolled
NCT04885998 2025-09-29AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)AmgenPhase 1 Completed23 enrolled 21 charts
NCT06064500 2025-03-10Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung CancerAmgenApproved for marketing